LLY
Eli Lilly and Company
LLY's fundamentals are strong: revenue grew 46% and it turned 23% of its revenue into free cash flow. At 46x earnings, it's trading in line with its usual 48x. Analysts expect that strong growth to continue.
SNGX
Soligenix, Inc.
There isn't enough reported data to score SNGX yet.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
SNGX Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Weak | |
| Unavailable | |
| Unavailable |
SNGX's revenue and profitability are currently weak. There isn't enough data to rate its cash flow and balance sheet.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
SNGX PE Valuation
SNGX has no meaningful PE right now: it lost money over the past year.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
SNGX Forward outlook
There aren't enough analyst estimates for SNGX to show an outlook.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the stronger earnings trend. Trailing diluted EPS is up 51% for LLY versus SNGX down 116%.
SNGX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2023 | -$31.84 | +$52.16 |
| Q2 2023 | -$48.48 | +$37.92 |
| Q1 2023 | -$58.72 | +$25.28 |
| Q4 2022 | -$76.96 | -$2.56 |
| Q3 2022 | -$84.00 | +$2.40 |
| Q2 2022 | -$86.40 | -$7.20 |
| Q1 2022 | -$84.00 | +$7.20 |
| Q4 2021 | -$74.40 | +$79.20 |
SNGX is still losing money, but far less than before: $5.17 per share over the past year, against $170.40 at its worst in early 2020.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the stronger quarterly revenue trend. Revenue is up 39% for LLY versus down 100% for SNGX.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY's operating margin was 34% last quarter, down 6.6 points from the same quarter a year ago.
SNGX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2024 | $2.3K | -99% |
| Q1 2024 | $117K | -54% |
| Q4 2023 | $244.8K | -33% |
| Q3 2023 | $130.4K | -21% |
| Q2 2023 | $206.9K | -9.5% |
| Q1 2023 | $257.2K | +37% |
| Q4 2022 | $366.1K | +33% |
| Q3 2022 | $166.1K | -11% |
SNGX's revenue has slid since its 2020 peak: $0 last quarter, down 100% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2024 | -74495% | -73707 points |
| Q1 2024 | -1809% | -973 points |
| Q4 2023 | -873% | +102 points |
| Q3 2023 | -1364% | +491 points |
| Q2 2023 | -788% | +697 points |
| Q1 2023 | -836% | +1398 points |
| Q4 2022 | -975% | +665 points |
| Q3 2022 | -1855% | -42 points |
SNGX's operating margin was −74495% last quarter, down 73707 points from the same quarter a year ago, near the bottom of its range since 2019.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the stronger cash trend. Its trailing FCF is up 259% versus its history, compared with SNGX at up 6.1%.
SNGX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q1 2026 | -$2.4M | -$510.7K |
| Q4 2025 | -$2.7M | -$514.2K |
| Q3 2025 | -$2.9M | -$22.8K |
| Q1 2025 | -$1.8M | -$504.5K |
| Q4 2024 | -$2.2M | -$404.6K |
| Q3 2024 | -$2.9M | -$224.1K |
| Q2 2024 | -$1.9M | +$5.5K |
| Q1 2024 | -$1.3M | +$823.8K |
SNGX has burned cash in almost every quarter: −$10M over the past year, against −$8M the year before.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over SNGX on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
SNGX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +39% | +6.2M shares |
| 1 year | +576% | +18.9M shares |
| 3 years | +12241% | +22M shares |
| 5 years | +17874% | +22M shares |
SNGX has 22M diluted shares, up 576% from a year ago.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
SNGX Net Leverage
SNGX's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
SNGX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 35.3 | Neutral |
| Stochastic | 17.2 | Oversold |
SNGX's weekly RSI is 35 (neutral) and its Stochastic is 17 (oversold).
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
SNGX PE vs Healthcare Sector
SNGX has no meaningful PE right now: it lost money over the past year.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over SNGX on trend strength, trading above more of its moving averages.
SNGX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $0.36 | 11% below |
| 20 week MA | $0.37 | 14% below |
| 50 week MA | $0.77 | 58% below |
| 100 week MA | $1.44 | 78% below |
| 200 week MA | $8.25 | 96% below |
SNGX is in a downtrend: it's below all five of its weekly moving averages, and 96% below its 200-week average.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over SNGX on returns for 2026, with the stronger performance.
SNGX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $340.8 | $321.6 | -5.6% |
| 2021 | $321.6 | $184.3 | -43% |
| 2022 | $184.3 | $154.9 | -16% |
| 2023 | $154.9 | $12.1 | -92% |
| 2024 | $12.1 | $2.89 | -76% |
| 2025 | $2.89 | $1.37 | -53% |
| 2026 YTD | $1.37 | $0.32 | -77% |
SNGX has finished every year since 2020 lower, and it's down 77% so far in 2026.